Doman Robert F Form 4 December 20, 2012

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Doman Robert F

(Last)

2. Issuer Name and Ticker or Trading

Symbol

5. Relationship of Reporting Person(s) to Issuer

DUSA PHARMACEUTICALS INC

[DUSA]

3. Date of Earliest Transaction

(Month/Day/Year) 12/20/2012

(Check all applicable)

\_X\_\_ Director X\_ Officer (give title below)

10% Owner Other (specify

DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE

(First)

(Street) 4. If Amendment, Date Original

(Middle)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

President and CEO

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

WILMINGTON, MA 01887

(City)	(State)	(Zip) Tabl	e I - Non-D	erivative Se	curiti	es Acqı	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	12/20/2012		U	138,286	D	\$8	0	D	
Common Stock	12/20/2012		U	19,750	D	\$8	0	I	by wife
Common Stock (1)	12/20/2012		U	528,400	D	\$8	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

**SEC 1474** (9-02)

#### Edgar Filing: Doman Robert F - Form 4

## displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of in Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercise Expiration Date (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Secu
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Ar Nu Sh
Non-qualified Stock Options	\$ 14.26	12/20/2012		D	50,000	01/03/2006	01/02/2015	Common Stock	5
Non-qualified Stock Options	\$ 15.9	12/20/2012		D	50,000	01/03/2006	01/02/2015	Common Stock	5
Non-qualified Stock Options	\$ 6.75	12/20/2012		D	50,000	03/27/2007	03/26/2016	Common Stock	5
Non-qualified Stock Options	\$ 3.37	12/20/2012		D	60,000	03/20/2008	03/20/2014	Common Stock	6
Non-qualified Stock Options	\$ 2.2	12/20/2012		D	28,500	05/09/2009	05/09/2015	Common Stock	2
Non-qualified Stock Options	\$ 1.22	12/20/2012		D	187,400	03/13/2010	03/13/2016	Common Stock	18
Non-qualified Stock Options	\$ 1.65	12/20/2012		D	130,000	03/05/2011	03/04/2017	Common Stock	13

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
coporaing of their state of	Director	10% Owner	Officer	Other		
Doman Robert F DUSA PHARMACEUTICALS, INC. 25 UPTON DRIVE WILMINGTON, MA 01887	X		President and CEO			

## **Signatures**

/s/ Robert F Doman	12/20/2012		
**Signature of Reporting Person	Date		

Reporting Owners 2

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These shares are restricted shares. Pursuant to the Agreement and Plan of Merger, dated as of November 8, 2012, by and among, Sun Pharmaceutical Industries Limited as assigned to Caraco Pharmaceutical Laboratories, Ltd., Caraco Acquisition Corporation and DUSA

- (1) Pharmaceuticals, Inc. (the "Merger Agreement"), immediately prior to the date and time the merger becomes effective, each restricted share that is then outstanding and unvested shall immediately vest and become nonforfeitable, all restrictions and conditions applicable thereto shall lapse, and each restricted share shall be treated in the same manner as each other share of Company Common Stock in the merger and is cancelled in exchange for the right to receive cash payment for each such restricted share of \$8.00.
- (2) These stock options were cancelled in accordance with the Merger Agreement, as the exercise price of the options was at or above \$8.00, no cash payment was provided.
  - Pursuant to the Merger Agreement, each in-the-money stock option, whether vested or unvested, that is outstanding immediately prior to the Acceptance Time shall become fully vested immediately prior to the Acceptance Time, and be cancelled as of the Acceptance Time in
- (3) exchange for the right to receive at such time a lump sum cash payment of an amount equal to (i) the Offer Price less (ii) the exercise price payable in respect of each such share of Company Common Stock issuable under such option, net of applicable taxes, if any, with respect to such option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.